Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Conditions
Interventions
Avelumab
Locations
74
United States
Cancer Treatment Centers of America - Western Regional Medical Center
Goodyear, Arizona, United States
Scottsdale Healthcare Corporation
Scottsdale, Arizona, United States
Pinnacle Oncology Hematology
Scottsdale, Arizona, United States
Highlands Oncology Group
Rogers, Arkansas, United States
Pacific Cancer Medical Center, Inc.
Anaheim, California, United States
California Cancer Associates for Research & Excellence, Inc
Encinitas, California, United States
Start Date
January 31, 2013
Primary Completion Date
December 16, 2019
Completion Date
December 16, 2019
Last Updated
December 20, 2021
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06307795
NCT06716138
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions